ALTO-100 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Jan 10, 2023 → Oct 24, 2024

NCT ID

NCT05712187

About ALTO-100 + Placebo

ALTO-100 + Placebo is a phase 2 stage product being developed by Alto Neuroscience for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT05712187. Target conditions include Major Depressive Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder were approved

Approved (20) Terminated (0) Active (0)

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅DuloxetineEli LillyApproved

✅duloxetineEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06656416	Phase 2	Recruiting	Oct 2, 2024	Oct 1, 2026	Bipolar Disorder I or II With a Major Depressive Episode
NCT05712187	Phase 2	Completed	Jan 10, 2023	Oct 24, 2024	Major Depressive Disorder

Competing Products

20 competing products in Major Depressive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	26
LY2216684	Eli Lilly	Phase 1	29
LY2216684	Eli Lilly	Phase 1	29
Duloxetine	Eli Lilly	Phase 3	40
LY2216684 + Digoxin	Eli Lilly	Phase 1	29
Duloxetine + Paroxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
Mirtazapine Tablets	Sun Pharmaceutical	Approved	43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Pramipexole ER + Escitalopram	Cipla	Phase 2	42
LY2216684 + Sertraline	Eli Lilly	Phase 1	29
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	29
LY2216684 + SSRI	Eli Lilly	Phase 3	40